A First-In-Human, Phase 1/2 Study Of CFI-402411, a Hematopoietic Progenitor Kinase-1 (HPK1) Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Malignancies
What is the purpose of this trial?
The purpose of this study is to test the safety of an investigational drug called CFI-402411 alone and in combination with pembrolizumab and to study its effects in patients with advanced solid tumors who have progressed following previous therapies.
- Trial withTreadwell Therapeutics, Inc.
- Start Date06/16/2022
- End Date12/01/2023
- Last Updated06/20/2022
- Study HIC#2000029001